STOCK TITAN
  1. Home
  2. Sec-filings
  3. VKTX
  4. [Form 4] Viking Therapeutics, Inc. Insider Trading Activity

Viking Therapeutics (NASDAQ: VKTX) COO stock award leads to tax-cover share sale

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Viking Therapeutics, Inc. reported that Chief Operating Officer Marianna Mancini received 31,667 shares of common stock on July 28, 2026, upon vesting of a performance restricted stock unit award originally granted on January 3, 2023, after achieving a non-financial performance goal; this vesting represented 33.33% of that award. On July 29, 2026, 18,217 shares were automatically sold on a non-discretionary basis solely to satisfy tax withholding obligations related to this vesting, at a weighted average price of $33.4652 per share, within a price range of $33.28 to $33.805. Reported holdings also include 120 shares acquired on May 20, 2026 under the company’s 2024 Employee Stock Purchase Plan.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Mancini Marianna
Role Chief Operating Officer
Sold 18,217 shs ($610K)
Type Security Shares Price Value
Sale Common Stock, par value $0.00001 per share F3, F4 18,217 $33.4652 $610K
Grant/Award Common Stock, par value $0.00001 per share F1, F2 31,667 $0.00 $0.00
Holdings After Transaction: Common Stock, par value $0.00001 per share — 422,760 shares (Direct)
Footnotes (4)
  1. F1. The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.
  2. F2. Includes 120 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan.
  3. F3. These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.
  4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.28 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.
RSU shares vested 31,667 shares Common stock issued on July 28, 2026 upon vesting of a performance RSU award
Vested portion of RSU award 33.33% Portion of the January 3, 2023 performance RSU award that vested on July 28, 2026
Shares sold to cover taxes 18,217 shares Automatically sold on July 29, 2026 to satisfy tax withholding obligations
Weighted average sale price $33.4652 per share Weighted average price for the July 29, 2026 tax-related share sales
Sale price range $33.28–$33.805 per share Price range of multiple transactions in the July 29, 2026 tax-related sale
ESPP shares included 120 shares Shares acquired May 20, 2026 under the 2024 Employee Stock Purchase Plan
performance restricted stock unit award financial
"reported securities were subject to a performance restricted stock unit award"
non-discretionary basis financial
"shares were automatically sold on a non-discretionary basis solely to satisfy"
tax withholding obligations financial
"sold on a non-discretionary basis solely to satisfy certain tax withholding obligations"
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Employee Stock Purchase Plan financial
"acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did Viking Therapeutics (VKTX) disclose about COO Marianna Mancini’s recent stock award?
Viking Therapeutics reported that COO Marianna Mancini received 31,667 shares of common stock on July 28, 2026 from a performance restricted stock unit award granted on January 3, 2023, when a specified non-financial performance goal was achieved and 33.33% of that award vested.

Why were Viking Therapeutics (VKTX) shares sold by COO Marianna Mancini on July 29, 2026?
On July 29, 2026, 18,217 shares held by COO Marianna Mancini were automatically sold on a non-discretionary basis solely to satisfy tax withholding obligations arising from the issuance of shares upon vesting of the earlier performance restricted stock unit award.

At what prices were the Viking Therapeutics (VKTX) shares sold to cover taxes?
The tax-related sale of 18,217 shares by COO Marianna Mancini used a weighted average price of $33.4652 per share. The shares were sold in multiple transactions at prices ranging from $33.28 to $33.805, as disclosed in the footnotes.

What portion of Marianna Mancini’s performance RSU award vested at Viking Therapeutics (VKTX)?
Viking Therapeutics disclosed that 33.33% of COO Marianna Mancini’s performance restricted stock unit award, granted on January 3, 2023, vested on July 28, 2026 after a non-financial performance goal was achieved, resulting in the issuance of 31,667 shares of common stock.

Did the Viking Therapeutics (VKTX) filing mention shares from an Employee Stock Purchase Plan?
Yes. The disclosure notes that the reported holdings include 120 shares acquired on May 20, 2026 under Viking Therapeutics’ 2024 Employee Stock Purchase Plan, indicating part of the COO’s position comes from employee share purchases.

Is the July 29, 2026 Viking Therapeutics (VKTX) share sale by the COO characterized as discretionary trading?
No. The company states the 18,217 shares sold on July 29, 2026 were automatically sold on a non-discretionary basis and used solely to satisfy tax withholding obligations tied to the vesting of a performance restricted stock unit award.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mancini Marianna
(Last)(First)(Middle)
C/O VIKING THERAPEUTICS, INC.
9920 PACIFIC HEIGHTS BLVD, SUITE 350
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [ VKTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.00001 per share07/28/2026A31,667(1)A$0440,977(2)D
Common Stock, par value $0.00001 per share07/29/2026S18,217(3)D$33.4652(4)422,760D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.
2. Includes 120 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan.
3. These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.28 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.
/s/ Michael Morneau, as Attorney-in-Fact07/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR